RCM Technologies (RCMT) Stock Forecast & Price Target

RCM Technologies is viewed positively because 2Q26 showed broad-based momentum, with revenue rising 20.2% year over year to $93.8M, adjusted EBITDA increasing to $9.3M, and adjusted EPS improving to $0.82 from $0.69. Its Specialty Health Care franchise remains the most stable and scalable engine, while Engineering rebounded sharply on Energy Services and EPC demand, and Life Sciences, Data and Solutions delivered higher-margin growth, supporting a favorable mix despite some gross margin compression. Strong operating cash flow of $13.5M in 2Q26 and over 54% growth in 1H26, plus ongoing share repurchases, highlight an asset-light model with improving financial flexibility and attractive execution.

RCM Technologies is exposed to multiple fundamental weaknesses that make its outlook negative, including integration risk from recent and potential future bolt-on acquisitions, which could strain financing and disrupt operations. Its competitive position also looks vulnerable because it faces larger, better-resourced rivals across end markets, while revenue is concentrated in North America and sensitive to a North American slowdown, cyclical engineering and construction demand, and labor retention challenges. In addition, client concentration and external dependencies heighten risk, as in 2020 the New York City Board of Education accounted for 10.6% of revenues and the top five customers made up 33.4%, leaving results vulnerable to economic cycles, regulation, and limited stock liquidity.